Biognosys

The group's meeting this week evidenced the ongoing shift towards analyzing proteins in the context of specific isoforms, complexes, and cells.

The recent agreement between Freenome and Biognosys suggests a role for proteomics as developers of genomic-based cancer detection tests look beyond ctDNA.

Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.

The agreement brings together Biognosys' Spectronaut Pulsar DIA software and Waters' SONAR data-independent acquisition mass spectrometry method.

The company said it plans to use the funds to extend its commercial operations and develop new products broadly aimed at the life sciences research market.

As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.

The agreement involves Thermo Fisher's Orbitrap mass specs and Biognosys' Spectronaut Pulsar software for data-independent acquisition studies.

The company has licensed the Limited Proteolysis technology developed by ETH Zurich Professor Paola Picotti, which can assess proteome-wide structural changes.

Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.

The firm, which will open a Boston office at the end of Q1, did not disclose the amount raised but said it was in the "mid-single-digit millions" of dollars.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.